JP2009504142A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504142A5 JP2009504142A5 JP2008525399A JP2008525399A JP2009504142A5 JP 2009504142 A5 JP2009504142 A5 JP 2009504142A5 JP 2008525399 A JP2008525399 A JP 2008525399A JP 2008525399 A JP2008525399 A JP 2008525399A JP 2009504142 A5 JP2009504142 A5 JP 2009504142A5
- Authority
- JP
- Japan
- Prior art keywords
- marker
- growth factor
- marker protein
- encoded
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003550 marker Substances 0.000 claims 51
- 108090000623 proteins and genes Proteins 0.000 claims 48
- 102000004169 proteins and genes Human genes 0.000 claims 31
- 238000000034 method Methods 0.000 claims 18
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 9
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 8
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims 8
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 8
- 150000001413 amino acids Chemical group 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 7
- 101800003838 Epidermal growth factor Proteins 0.000 claims 6
- 239000004010 HER dimerization inhibitor Substances 0.000 claims 6
- 229940116977 epidermal growth factor Drugs 0.000 claims 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 4
- -1 -Amphiregulin Proteins 0.000 claims 3
- 101150029707 ERBB2 gene Proteins 0.000 claims 3
- 108700020796 Oncogene Proteins 0.000 claims 3
- 102000043276 Oncogene Human genes 0.000 claims 3
- 102000007299 Amphiregulin Human genes 0.000 claims 2
- 108010033760 Amphiregulin Proteins 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 1
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 238000003365 immunocytochemistry Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05017663 | 2005-08-12 | ||
| PCT/EP2006/004950 WO2007019899A2 (en) | 2005-08-12 | 2006-05-24 | Method for predicting the response to a treatment with a her dimerization inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009504142A JP2009504142A (ja) | 2009-02-05 |
| JP2009504142A5 true JP2009504142A5 (OSRAM) | 2009-05-28 |
Family
ID=35511140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525399A Pending JP2009504142A (ja) | 2005-08-12 | 2006-05-24 | 治療に対する応答を予測するための方法 |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7700299B2 (OSRAM) |
| EP (2) | EP2196547B1 (OSRAM) |
| JP (1) | JP2009504142A (OSRAM) |
| KR (2) | KR20080034922A (OSRAM) |
| CN (2) | CN101705287A (OSRAM) |
| AR (1) | AR057323A1 (OSRAM) |
| AT (2) | ATE493514T1 (OSRAM) |
| AU (2) | AU2006281746B2 (OSRAM) |
| BR (1) | BRPI0615001A2 (OSRAM) |
| CA (1) | CA2616913A1 (OSRAM) |
| CL (1) | CL2010000720A1 (OSRAM) |
| CR (1) | CR9686A (OSRAM) |
| CY (1) | CY1111612T1 (OSRAM) |
| DE (1) | DE602006019265D1 (OSRAM) |
| DK (1) | DK1915460T3 (OSRAM) |
| EC (1) | ECSP088171A (OSRAM) |
| ES (1) | ES2356066T3 (OSRAM) |
| HR (1) | HRP20110171T1 (OSRAM) |
| IL (1) | IL188923A0 (OSRAM) |
| MA (1) | MA31549B1 (OSRAM) |
| MX (1) | MX2008001926A (OSRAM) |
| NO (1) | NO20080371L (OSRAM) |
| NZ (1) | NZ565270A (OSRAM) |
| PL (1) | PL1915460T3 (OSRAM) |
| PT (1) | PT1915460E (OSRAM) |
| RS (1) | RS51859B (OSRAM) |
| RU (2) | RU2408735C2 (OSRAM) |
| SI (1) | SI1915460T1 (OSRAM) |
| TW (1) | TW200741010A (OSRAM) |
| UA (1) | UA93989C2 (OSRAM) |
| WO (1) | WO2007019899A2 (OSRAM) |
| ZA (1) | ZA201102688B (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| MXPA02011379A (es) * | 2000-05-19 | 2003-06-06 | Genentech Inc | Ensayo de deteccion de genes para mejorar la probabilidad de una respuesta efectiva a terapia de cancer con el antagonista erbb. |
| GT200500155A (es) * | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| KR20190126461A (ko) | 2004-07-22 | 2019-11-11 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CN101115849A (zh) * | 2004-12-07 | 2008-01-30 | 健泰科生物技术公司 | 选择her抑制剂疗法的患者 |
| KR20200058588A (ko) | 2005-01-21 | 2020-05-27 | 제넨테크, 인크. | Ｈｅｒ 항체의 고정 용량 투여법 |
| MY152164A (en) * | 2005-02-23 | 2014-08-15 | Genentech Inc | Extending time to disease progression or survival in cancer patients |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| EP1917528B1 (en) * | 2005-08-24 | 2011-08-17 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| KR20150039212A (ko) * | 2007-03-02 | 2015-04-09 | 제넨테크, 인크. | 낮은 ｈｅｒ３ 발현을 기초로 한 ｈｅｒ 이량체화 억제제에 대한 반응 예측 |
| JP5433189B2 (ja) * | 2007-09-28 | 2014-03-05 | 承一 尾崎 | Ｍｐｏ−ａｎｃａ関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法 |
| EP2235536A4 (en) | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2-DIAGNOSTIC PROCEDURE |
| US8637026B2 (en) * | 2007-12-26 | 2014-01-28 | Vaccinex, Inc. | Anti-C35 antibody combination therapies and methods |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| JP2011517555A (ja) * | 2008-03-14 | 2011-06-16 | ジェネンテック， インコーポレイテッド | 薬剤耐性に関連する遺伝的変異 |
| NZ589143A (en) | 2008-05-14 | 2012-02-24 | Genomic Health Inc | Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| ES2637411T3 (es) | 2008-12-01 | 2017-10-13 | Laboratory Corporation Of America Holdings | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 |
| KR20110120890A (ko) * | 2009-01-15 | 2011-11-04 | 래버러토리 코포레이션 오브 아메리카 홀딩스 | Ｈｅｒ－２ 발현의 측정에 의한 환자 반응의 결정 방법 |
| SG172983A1 (en) | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| WO2011132182A1 (en) * | 2010-04-18 | 2011-10-27 | Yeda Research And Development Co. Ltd. | MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES |
| PT2661266T (pt) * | 2011-01-07 | 2020-11-30 | Anji Pharma Us Llc | Terapias com base em ligandos do recetor quimiossensorial |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| AU2012318541B2 (en) * | 2011-10-06 | 2018-04-12 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
| BR112014007521A8 (pt) | 2011-10-14 | 2018-04-10 | Genentech Inc | método para estender a sobrevida livre de progressão em uma população com câncer de mama, artigo de fabricação, método para produção de um artigo de fabricação, para garantir o uso seguro e efetivo de pertuzumabe, de tratar câncer de mama, bolsa intravenosa, método de tratar câncer gástrico, de tratar adenocarcinoma do estômago e de melhora de sobrevida |
| CN110693868A (zh) | 2012-01-06 | 2020-01-17 | 埃尔舍利克斯治疗公司 | 双胍组合物和治疗代谢性病症的方法 |
| CN104349773A (zh) | 2012-01-06 | 2015-02-11 | 埃尔舍利克斯治疗公司 | 用于治疗代谢性病症的组合物和方法 |
| EA201591643A1 (ru) | 2013-04-16 | 2016-02-29 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| CA2919477A1 (en) * | 2013-07-31 | 2015-02-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules |
| EP2876442A1 (en) | 2013-11-22 | 2015-05-27 | Institut de Cancérologie de l'Ouest | Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer |
| KR20160141857A (ko) | 2014-04-25 | 2016-12-09 | 제넨테크, 인크. | 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법 |
| WO2016011343A1 (en) | 2014-07-17 | 2016-01-21 | The Trustees Of The University Of Pennsylvania | Her3 peptides and dendritic cell vaccines |
| HUE068105T2 (hu) | 2015-05-30 | 2024-12-28 | Hoffmann La Roche | Eljárások korábban kezeletlen her2-pozitív metasztatikus emlõrák kezelésére |
| JP2018527286A (ja) * | 2015-07-17 | 2018-09-20 | ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． | 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定 |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| CN105403704A (zh) * | 2015-12-31 | 2016-03-16 | 苏州市博纳泰科生物技术有限公司 | Her-2的荧光免疫层析检测方法及试剂盒 |
| KR20190075114A (ko) | 2016-11-04 | 2019-06-28 | 제넨테크, 인크. | Her2-양성 유방암의 치료 |
| KR102313262B1 (ko) | 2016-12-28 | 2021-10-14 | 제넨테크, 인크. | 진행성 her2 발현 암의 치료 |
| US10849849B2 (en) | 2017-01-17 | 2020-12-01 | Genentech Inc. | Subcutaneous HER2 antibody formulations |
| ES2969041T3 (es) | 2017-03-02 | 2024-05-16 | Genentech Inc | Tratamiento adyuvante del cáncer de mama positivo para HER2 |
| AU2018258263A1 (en) | 2017-04-24 | 2019-10-24 | Genentech, Inc. | ErbB2/Her2 mutations in the transmembrane or juxtamembrane domain |
| US20210189398A1 (en) | 2018-05-25 | 2021-06-24 | Bioneer Corporation | Amphiregulin gene-specific double-stranded oligonucleotide and composition for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same |
| MX2022015884A (es) | 2020-06-29 | 2023-04-03 | Genentech Inc | Combinacion de dosis fija de pertuzumab mas trastuzumab. |
| CA3264494A1 (en) * | 2022-08-09 | 2024-02-15 | Heligenics Inc. | METHOD FOR EVALUATING THE CLINICAL RELEVANCE OF A GENETIC VARIANCE |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US6759217B2 (en) * | 1996-03-26 | 2004-07-06 | Oncomedx, Inc. | Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer |
| CN100415772C (zh) | 1996-10-18 | 2008-09-03 | 基因技术股份有限公司 | 抗ErbB2抗体 |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| MXPA01013458A (es) | 1999-06-25 | 2002-07-30 | Genentech Inc | Anticuerpos humanizados anti-erbb2 y tratamiento con anticuerpos anti-erbb2. |
| WO2003078662A1 (en) * | 2002-03-13 | 2003-09-25 | Genomic Health | Gene expression profiling in biopsied tumor tissues |
| US20040248151A1 (en) * | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
| GB0215509D0 (en) | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
| EP2263691B1 (en) * | 2002-07-15 | 2012-08-29 | F.Hoffmann-La Roche Ag | Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4) |
| DE03808454T1 (de) * | 2002-12-11 | 2006-01-26 | Ventana Medical Systems, Inc., Tucson | Verfahren zur voraussage der auswirkung der her2-gezielten therapie |
| CA2515096A1 (en) | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| WO2004087887A2 (en) | 2003-04-01 | 2004-10-14 | Monogram Biosciences, Inc. | Intracellular complexes as biomarkers |
| EP2348110B1 (en) | 2003-05-30 | 2013-03-27 | OncoTherapy Science, Inc. | Process for screening a drug response in cancer patients |
| WO2005011607A2 (en) | 2003-08-01 | 2005-02-10 | Smithkline Beecham Corporation | Treatment of cancers expressing p95 erbb2 |
| EP1682675A2 (en) | 2003-10-28 | 2006-07-26 | Bayer HealthCare AG | Methods and compositions for the response prediction of malignant neoplasia to treatment |
| TWM256978U (en) * | 2004-04-02 | 2005-02-11 | Nventec Appliances Corp | Electronic device |
| CN101115849A (zh) * | 2004-12-07 | 2008-01-30 | 健泰科生物技术公司 | 选择her抑制剂疗法的患者 |
| RU2300111C2 (ru) * | 2005-06-15 | 2007-05-27 | Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) | Способ прогнозирования течения заболевания раком молочной железы |
-
2006
- 2006-05-19 US US11/438,033 patent/US7700299B2/en not_active Expired - Fee Related
- 2006-05-23 TW TW095118273A patent/TW200741010A/zh unknown
- 2006-05-24 DK DK06743052.0T patent/DK1915460T3/da active
- 2006-05-24 CN CN200910204668A patent/CN101705287A/zh active Pending
- 2006-05-24 PT PT06743052T patent/PT1915460E/pt unknown
- 2006-05-24 JP JP2008525399A patent/JP2009504142A/ja active Pending
- 2006-05-24 AR ARP060102149A patent/AR057323A1/es not_active Application Discontinuation
- 2006-05-24 CN CNA2006800289513A patent/CN101405405A/zh not_active Withdrawn
- 2006-05-24 AT AT06743052T patent/ATE493514T1/de active
- 2006-05-24 AU AU2006281746A patent/AU2006281746B2/en not_active Ceased
- 2006-05-24 HR HR20110171T patent/HRP20110171T1/hr unknown
- 2006-05-24 SI SI200630946T patent/SI1915460T1/sl unknown
- 2006-05-24 WO PCT/EP2006/004950 patent/WO2007019899A2/en not_active Ceased
- 2006-05-24 KR KR1020087003440A patent/KR20080034922A/ko not_active Ceased
- 2006-05-24 CA CA002616913A patent/CA2616913A1/en not_active Abandoned
- 2006-05-24 ES ES06743052T patent/ES2356066T3/es active Active
- 2006-05-24 DE DE602006019265T patent/DE602006019265D1/de active Active
- 2006-05-24 EP EP10156100A patent/EP2196547B1/en active Active
- 2006-05-24 MX MX2008001926A patent/MX2008001926A/es active IP Right Grant
- 2006-05-24 BR BRPI0615001-2A patent/BRPI0615001A2/pt not_active IP Right Cessation
- 2006-05-24 RU RU2008108907/10A patent/RU2408735C2/ru not_active IP Right Cessation
- 2006-05-24 EP EP06743052A patent/EP1915460B1/en active Active
- 2006-05-24 AT AT10156100T patent/ATE539171T1/de active
- 2006-05-24 PL PL06743052T patent/PL1915460T3/pl unknown
- 2006-05-24 NZ NZ565270A patent/NZ565270A/en not_active IP Right Cessation
- 2006-05-24 RS RS20110132A patent/RS51859B/sr unknown
- 2006-05-24 UA UAA200803055A patent/UA93989C2/ru unknown
- 2006-05-24 KR KR1020117011685A patent/KR20110074921A/ko not_active Ceased
-
2008
- 2008-01-21 IL IL188923A patent/IL188923A0/en unknown
- 2008-01-21 NO NO20080371A patent/NO20080371L/no not_active Application Discontinuation
- 2008-01-24 CR CR9686A patent/CR9686A/es not_active Application Discontinuation
- 2008-02-06 MA MA30621A patent/MA31549B1/fr unknown
- 2008-02-11 EC EC2008008171A patent/ECSP088171A/es unknown
-
2009
- 2009-11-24 US US12/624,443 patent/US20100112603A1/en not_active Abandoned
-
2010
- 2010-04-19 RU RU2010115252/10A patent/RU2010115252A/ru not_active Application Discontinuation
- 2010-07-06 CL CL2010000720A patent/CL2010000720A1/es unknown
-
2011
- 2011-03-15 CY CY20111100286T patent/CY1111612T1/el unknown
- 2011-04-11 ZA ZA2011/02688A patent/ZA201102688B/en unknown
- 2011-05-19 AU AU2011202339A patent/AU2011202339A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009504142A5 (OSRAM) | ||
| RU2408735C2 (ru) | Способ предсказания ответа на лечение | |
| ES2370054T3 (es) | Biomarcadores y procedimientos para determinar la sensibilidad a moduladores del receptor del factor de crecimiento epidérmico. | |
| JP2009521215A5 (OSRAM) | ||
| CN107076749B (zh) | 转移性结直肠癌抗血管发生治疗相关预测和预后生物标志 | |
| KR20130091750A (ko) | 유방암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커 | |
| MX2007014815A (es) | Metodos de inmunoanalisis mejorados. | |
| JP2015528295A5 (OSRAM) | ||
| EP1996940A4 (en) | DETECTION OF CANCER DUE TO INCREASED BCL-2 CONCENTRATIONS | |
| NZ592552A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| KR20130091746A (ko) | 췌장암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커 | |
| US20210310080A1 (en) | Composition for diagnosing cancer using potassium channel proteins | |
| US20230047712A1 (en) | Methods of Treatments Based Upon Molecular Response to Treatment | |
| CN103898205A (zh) | 半胱氨酸蛋白酶抑制剂sn的应用 | |
| CN108138238A (zh) | 用于检测胰腺癌的组合物和方法 | |
| WO2014198995A1 (es) | Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas | |
| NZ593392A (en) | Biomarker for detecting bladder cancer | |
| JP5702944B2 (ja) | バイオマーカー | |
| US20180136216A1 (en) | Biomarkers for a Combination Therapy Comprising Lenvatinib and Everolimus | |
| CN116397020B (zh) | 生物标志物在预测磺酸类烷化剂诱导骨髓损伤敏感性中的应用 | |
| KR20240151659A (ko) | 폐암 치료의 반응 및 효능 평가와 예후 예측용 바이오 마커 | |
| WO2020071457A1 (en) | Biomarkers for a combination therapy comprising lenvatinib and everolimus | |
| DK2440931T3 (en) | A method for determining the risk of developing brain metastasis and to a kit for carrying out the method | |
| KR102136747B1 (ko) | 장형 위암의 예후 진단 마커 | |
| KR20220148615A (ko) | 위암의 예후 예측 방법 |